Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals-Reference-Cited by-同舟云学术

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

Published:2008-07 Issue:2 Volume:265 Page:307-317
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Zhu Jian-quan,Zhong Wen-zhao,Zhang Guo-chun,Li Rong,Zhang Xu-chao,Guo Ai-lin,Zhang Yi-fang,An She-juan,Mok Tony S.,Wu Yi-long

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference42 articles.

1. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results;Breathnach;J. Clin. Oncol.,2001

2. Erlotinib in lung cancer – molecular and clinical predictors of outcome;Tsao;N. Engl. J. Med.,2005

3. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer;Takano;J. Clin. Oncol.,2005

4. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers;Shigematsu;Int. J. Cancer,2006

5. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China;Wu;J. Thorac. Oncol.,2007

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment;Lung Cancer;2024-04

2. EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue;Chemical Biology & Drug Design;2024-04

3. Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib;Therapeutic Advances in Medical Oncology;2024-01

4. Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib;Respiratory Medicine Case Reports;2024

5. Silencing of lncRNA LOC105376794 promotes migration, invasion, and gefitinib resistance of lung adenocarcinoma cells with EGFR 19del mutation by ATF4/CHOP axis and ERK phosphorylation;Neoplasma;2024